Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Plerixafor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 10 Apr 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 12 Dec 2017 Results (n=13) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology